ValGenesis offers ValGenesis Smart GxP, a cloud-based, AI-enabled platform for end-to-end validation and process lifecycle digitalization in regulated life sciences industries. The platform unifies risk-based validation and process automation to streamline compliance, traceability, and efficiency at scale. The company says it is trusted by 30 of the world’s top 50 life sciences companies and has delivered double-digit year-over-year growth. ValGenesis recently launched an AI-assisted validation program and holds a growing number of issued patents supporting its product roadmap. Current plans include accelerating global expansion across North America, Europe, and Asia‑Pacific, strategic hiring, regional partner expansion, and customer success initiatives to meet rising demand. The company is backed by investment funds managed by Morgan Stanley Expansion Capital. San Francisco-based ValGenesis offers the industry's first proven, fully paperless Enterprise Validation Lifecycle Management System (VLMS) delivered via a private secured Cloud. The platform is positioned as a system of record for validation, is validated, fully configurable, and rapidly deployable. ValGenesis says it is the inventor and first-mover to digitize the validation lifecycle and is compliant with U.S. FDA 21 CFR Part 11 and Annex 11. The company reports being trusted by over 30 of the top 50 global life science companies. With the new funding, ValGenesis plans to bolster sales, accelerate innovation in digital validation technologies (including AI, IoT, AR-enabled capabilities cited by the company), and expand global deployment. The company also highlights prior product development activity in 2020 that augmented its VLMS with cutting-edge digital validation technologies.

Total raised

$40M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2025